Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis

December 11, 2021
By Conor Killmurray
News
Article
Conference|ASH Annual Meeting & Exposition: Lymphoma

Anti-tumor activity coupled with a manageable safety profile was noted with the combination of ibrutinib plus loncastuximab tesirine for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma at an interim analysis of the LOTIS-3 trial presented at 2021 ASH.

An interim analysis of the of the ongoing phase 2 LOTIS-3 trial (NCT03684694) that was presented at the 2021 American Society of Hematology (ASH) Annual Meeting revealed promising efficacy and encouraging safety with the combination of ibrutinib (Imbruvica) plus loncastuximab tesirine (Zynlonta) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

These results have led the study authors to amend the study protocol to administer loncastuximab at each cycle of therapy to see if it along with ibrutinib improves outcomes in the patient population.

This interim analysis of the phase 2 open-label single-arm study identified a complete response rate (CRR) of 34.3% (95% CI, 19.1%–52.2%) among the overall DLBCL cohort. Moreover, there was a 57.1% (95% CI, 39.4%–73.7%) overall response rate (ORR) in the overall DLBCL cohort with a median duration of response (DOR) of 5.49 months, while DOR had not been reached in the non-germinal center B-cell–like DLBCL (non-GCB DLBCL), and GCB DLBCL cohorts.

“In the overall DLBCL cohort, 57% of the patients responded with a 34% complete response and 22% partial response,” said lead study author Carmelo Carlo-Stella, MD, a full professor of hematology at Humanitas University in Italy, discussing the ORR in a virtual presentation of the interim analysis data at ASH. “(Overall response) was 45% in the non-GCB cohort and 77% in the GCB DCBL cohort with a 27% complete response in the non-GCB cohort and a 46% complete response in the GCB cohort.”

The overall DLBCL cohort, irrespective of the cell of origin, consisted of 35 patients while 22 of the patients had non-GCB DLBCL, and 13 patients had GCB DLBCL. In the overall DLBCL cohort, patients had a median age of 72 years (range 19-82) and had previously received a median of 3 prior therapies (range, 1-6). At the time of the analysis, patients had received a median of 2 cycles (range, 1-6) of loncastuximab and 4 cycles (range, 1-10) of ibrutinib.

Assessing the overall DLBCL cohort, median DOR was different for each therapy with loncastuximab at 49 days (range, 1-246) and 97.5 days (range, 13-386) on ibrutinib. While DOR was not yet reached in the other cohorts, patients in the non-GCB DLBCL cohort had a 3-month DOR during the first quartile of treatment. According to Carlo-Stella, who is also a principal investigator at the Lab of Cancer Experimental Therapeutics at the Humanitas Research Hospital, 6 patients from the GCB DLBCL cohort were experiencing an ongoing response at the time of analysis, compared to 3 in the non-GCB DLBCL cohort.

Patients in this analysis were treated with 60 μg/kg of loncastuximab every 3 weeks for 2 cycles plus 560 mg/day of oral ibrutinib for up to 1 year. Patients who experienced a complete response, partial response, or stable disease were given an additional dose of loncastuximab at day 1 of cycles 5, 6, 9, and 10. The primary objective of the study was to evaluate the CRR achieved with loncastuximab plus ibrutinib with a safety evaluation.

The safety results, according to Carlo-Stella, were consistent with previous studies of the therapy with 94% of the patients experiencing treatment-emergent adverse events (TEAE) of any grade. Thrombocytopenia was the most common TEAE among all grades with 68.2% (n = 15) of patients in the non-GCB cohort experiencing it, 46.2% (n = 6) in the GCB cohort, and 60% (n = 21) in the overall cohort. Dose reduction, interruptions, or discontinuation due to TEAEs were observed in 57.1% of all patients. Grade 3 or higher TEAEs were seen in 72.7% (16) of patients in the non-GCB cohort, 15.4% (2) in the GCB cohort, and 51.4% (18), in the overall DLBCL cohort. The most common grade 3 or higher TEAE was neutropenia with 8 patients experiencing it, while 3 patients had contracted COVID-19.

While Carlo-Stella said the low CRR in the non-GCB cohort was surprising, he noted that it could be because the sample size was small. However, he said, investigators plan to add ibrutinib to more cycles of treatment and continue the study.

Reference

Carlo-Stella C, Zinzani P, Janakiram M, et al. Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3). Presented at: 63rd Annual American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021. Abstract 54. Accessed December 11, 2021. https://bit.ly/3GGCalP

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 1st 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
August 1st 2025
Article

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
August 1st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
August 1st 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
August 1st 2025
Article

A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.

Related Content

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 1st 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
August 1st 2025
Article

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
August 1st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
August 1st 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
August 1st 2025
Article

A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.